A detailed history of Sterling Capital Management LLC transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Sterling Capital Management LLC holds 68 shares of TCRX stock, worth $209. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68
Holding current value
$209
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.97 - $7.49 $337 - $509
68 New
68 $339,000

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $58.3M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Sterling Capital Management LLC Portfolio

Follow Sterling Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sterling Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sterling Capital Management LLC with notifications on news.